Prostatic Diseases  >>  Provenge (sipuleucel-T)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Provenge (sipuleucel-T) / Bausch Health
NCT01274572: Blood for Immune Response to Provenge® in HRPC

Withdrawn
N/A
0
US
Mary Crowley Medical Research Center
Prostate Cancer
01/11
06/11
NCT02042053: PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Terminated
N/A
10
US
PET/CT, PET/MRI
NYU Langone Health, Dendreon
Prostate Cancer
05/15
10/15
NCT02237170: Immune Monitoring on Sipuleucel-T

Completed
N/A
36
US
Icahn School of Medicine at Mount Sinai
Prostate Cancer
12/16
12/16
NCT02232230: A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Completed
N/A
20
US
Provenge
GenesisCare USA, Dendreon
Castrate Refractory Metastatic Prostate Cancer (mCRPC)
06/18
06/18

Download Options